Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down

Reuters10-16

Carisma <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down

Carisma Therapeutics Inc. has announced new separation agreements for its President and CEO, Steven Kelly, and Chief Scientific Officer, Michael Klichinsky, following the company's decision to wind down operations. Under the agreements, Dr. Klichinsky will receive twelve months of base salary paid over a year, a lump sum payment of his pro-rated 2025 target bonus, and monthly taxable payments of $2,245 for up to 12 months to assist with health insurance costs. Mr. Kelly will receive a lump sum equal to twelve months of his base salary, a pro-rated lump sum of his 2025 target bonus, and monthly taxable payments of $3,757 for up to 12 months. These payments are subject to the execution and non-revocation of a release of claims and certain post-employment obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-099740), on October 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575008756?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575008756","market":"nz","top_or_hot":-1,"title":"Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Carisma <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Carisma Therapeutics Inc. has announced new separation agreements for its President and CEO, Steven Kelly, and Chief Scientific Officer, Michael Klichinsky, following the company's decision to wind down operations. Under the agreements, Dr. Klichinsky will receive twelve months of base salary paid over a year, a lump sum payment of his pro-rated 2025 target bonus, and monthly taxable payments of $2,245 for up to 12 months to assist with health insurance costs. Mr. Kelly will receive a lump sum equal to twelve months of his base salary, a pro-rated lump sum of his 2025 target bonus, and monthly taxable payments of $3,757 for up to 12 months. These payments are subject to the execution and non-revocation of a release of claims and certain post-employment obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-099740), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCarisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Carisma <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Carisma Therapeutics Inc. has announced new separation agreements for its President and CEO, Steven Kelly, and Chief Scientific Officer, Michael Klichinsky, following the company's decision to wind down operations. Under the agreements, Dr. Klichinsky will receive twelve months of base salary paid over a year, a lump sum payment of his pro-rated 2025 target bonus, and monthly taxable payments of $2,245 for up to 12 months to assist with health insurance costs. Mr. Kelly will receive a lump sum equal to twelve months of his base salary, a pro-rated lump sum of his 2025 target bonus, and monthly taxable payments of $3,757 for up to 12 months. These payments are subject to the execution and non-revocation of a release of claims and certain post-employment obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-099740), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CARM","symbol_name":"Carisma Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL6mjjQ:1","article_id":"2575008756","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575008756","pubTimestamp":1760559502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CARM":"Carisma Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Carisma Therapeutics宣布与首席执行官和CSO达成离职协议，详细说明了裁员期间的遣散费和按比例分配的奖金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARM":0.9},"content_text":"Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down\n    \n\n        Carisma Therapeutics Inc. has announced new separation agreements for its President and CEO, Steven Kelly, and Chief Scientific Officer, Michael Klichinsky, following the company's decision to wind down operations. Under the agreements, Dr. Klichinsky will receive twelve months of base salary paid over a year, a lump sum payment of his pro-rated 2025 target bonus, and monthly taxable payments of $2,245 for up to 12 months to assist with health insurance costs. Mr. Kelly will receive a lump sum equal to twelve months of his base salary, a pro-rated lump sum of his 2025 target bonus, and monthly taxable payments of $3,757 for up to 12 months. These payments are subject to the execution and non-revocation of a release of claims and certain post-employment obligations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-099740), on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575008756","isCrawlerRequest":true}